SHIMIZU Kyoko
Department Other, Other Position |
|
Article types | Original article |
Language | English |
Peer review | Peer reviewed |
Title | Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. |
Journal | Formal name:Cancer chemotherapy and pharmacology Abbreviation:Cancer Chemother Pharmacol ISSN code:(1432-0843)0344-5704(Linking) |
Domestic / Foregin | Foregin |
Volume, Issue, Page | 82(2),pp.245-250 |
Author and coauthor | TAHARA Junko,SHIMIZU Kyoko,OTSUKA Nao,AKAO Junichi,TAKAYAMA Yukiko,TOKUSHIGE Katsutoshi |
Authorship | 2nd author,Corresponding author |
Publication date | 2018/08 |
Summary | Although G-nab and FFX are effective treatments for advanced pancreatic cancer, the G-nab group had a higher 1-year survival rate, and G-nab can be more safely administered to older patients. |
DOI | 10.1007/s00280-018-3611-y |
PMID | 29846765 |